Tag: Blood Cancers
Search News
Combining medicine with blood cancer research
3rd September 2021
This Blood Cancer Awareness Month, we spoke with Dr John Riches, Clinical Senior Lecturer at Barts Cancer Institute (BCI), Queen Mary University of London. Dr Riches is a clinician scientist who splits his time between BCI where he leads a group researching blood cancer in our Centre for Haemato-Oncology and directs the MSc Cancer & Clinical Oncology Programme, and St Bartholemew’s Hospital where he treats blood cancer patients.
Read more
Miguel Ganuza receives ASH Global Research Award
24th August 2021
Congratulations to Dr Miguel Ganuza from Barts Cancer Institute, Queen Mary University of London, who has been selected by the American Society of Hematology (ASH) to receive the 2021 ASH Global Research Award. Dr Ganuza is one of twelve talented early-career investigators selected for this award.
Read more
Understanding the role of the bone marrow in blood cell health and disease
3rd December 2020
Congratulations to Dr Miguel Ganuza from Barts Cancer Institute’s Centre for Haemato-Oncology who is the recipient of a Career Development Award from the Medical Research Council. The award of approximately £1.5 million over 5 years will fund a research project that will investigate how the bone marrow supports blood stem cells and how changes within the bone marrow can drive the development of diseases, such as leukaemia.
Read more
Covid-19 and blood cancer
3rd June 2020
One of the first studies to investigate the outcome of Covid-19 infection in patients with blood cancer has been conducted by clinical researchers from Barts Cancer Institute, Queen Mary University of London, and Barts Health NHS Trust.
Read more
New and valuable insights into familial myeloid leukaemia
3rd March 2020
Research has identified new genetic features implicated in a type of blood cancer known as familial myeloid leukaemia. The study, published in Nature Communications, offers novel insights into the biology of this inherited cancer, and provides a framework to inform how to more effectively manage at-risk individuals and patients affected by this type of blood malignancy.
Read more